{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:19:24Z","timestamp":1784287164842,"version":"3.55.0"},"reference-count":51,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Malignant peritoneal mesothelioma (MPeM) is a rare malignancy and represents 5% to 30% of malignant mesothelioma cases. The primary curative therapy for MPeM is radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), with the strongest predictor of long-term survival being complete cytoreduction. There is a paucity of high-quality evidence available to guide management in MPeM; however, NCCN Guidelines for the management of MPeM were updated this year. In well-selected patients, 5-year overall survival exceeds 65%, but achieving optimal results requires careful preoperative evaluation and expert surgical management. Preoperative patient selection includes histology review and staging with cross-sectional imaging. Ideal candidates for curative intent surgery are those with epithelioid MPeM, a low peritoneal cancer index, and a good performance status. Contraindications to curative intent surgery include the sarcomatoid MPeM, distant metastases, extensive nodal metastases, and extensive small bowel serosal or mesentery involvement not amenable to complete cytoreduction. Those with biphasic histology, bicavitary disease, and metastatic lymphadenopathy may be considered for surgery following response to neoadjuvant therapy. CRS involves resection of all peritoneal disease, the extent of which varies case by case. Key aspects involve careful evaluation of all peritoneal surfaces, complete parietal peritonectomy and omentectomy, and evaluating suspicious abdominal lymph node basins. Once maximum cytoreduction is achieved, HIPEC is performed using a platinum-based perfusate. Postoperative protocols are recommended to optimize recovery and mitigate HIPEC-specific complications, namely chemotherapy-mediated nephrotoxicity and bone marrow suppression.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7055","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T19:35:29Z","timestamp":1694028929000},"page":"981-986","source":"Crossref","is-referenced-by-count":11,"title":["Principles of Surgical Management of Peritoneal Mesothelioma"],"prefix":"10.6004","volume":"21","author":[{"given":"Jessica A.","family":"Steadman","sequence":"first","affiliation":[{"name":"Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis E.","family":"Grotz","sequence":"additional","affiliation":[{"name":"Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Crit Rev Toxicol","first-page":"576","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005","volume":"39","author":"Price B","year":"2009","unstructured":"Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576\u2013588."},{"key":"B2","series-title":"Cancer Causes Control","first-page":"935","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005","volume":"20","author":"Moolgavkar SH","year":"2009","unstructured":"Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005. Cancer Causes Control 2009;20:935\u2013944."},{"key":"B4","series-title":"Eur J Cancer","first-page":"3140","article-title":"Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti D","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD,  Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140\u20133148."},{"key":"B5","series-title":"World J Gastrointest Oncol","first-page":"36","article-title":"Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"2","author":"Baratti D","year":"2010","unstructured":"Baratti D, Kusamura S, Laterza B,  Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol 2010;2:36\u201343."},{"key":"B6","series-title":"Surgery","first-page":"779","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander HR Jr","year":"2013","unstructured":"Alexander HR Jr, Bartlett DL, Pingpank JF,  Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013;153:779\u2013786."},{"key":"B7","series-title":"Ann Surg Oncol","first-page":"2666","article-title":"Long-term survival in patients treated with cytoreduction and heated intraperitoneal chemotherapy for peritoneal mesothelioma at a single high-volume center","volume":"30","author":"Valenzuela CD","year":"2023","unstructured":"Valenzuela CD, Solsky IB, Erali RA,  Long-term survival in patients treated with cytoreduction and heated intraperitoneal chemotherapy for peritoneal mesothelioma at a single high-volume center. Ann Surg Oncol 2023;30:2666\u20132675."},{"key":"B8","series-title":"J Clin Oncol","first-page":"6237","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan TD","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D,  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237\u20136242."},{"key":"B9","series-title":"Ann Surg Oncol","first-page":"1840","article-title":"Conditional survival following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: an analysis from the US HIPEC Collaborative","volume":"30","author":"Beal EW","year":"2023","unstructured":"Beal EW, Srinivas S, Shen C,  Conditional survival following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: an analysis from the US HIPEC Collaborative. Ann Surg Oncol 2023;30:1840\u20131849."},{"key":"B10","series-title":"Cancer","first-page":"2510","article-title":"The Chicago Consensus Guidelines for peritoneal surface malignancies: introduction","volume":"126","author":"Turaga K","year":"2020","unstructured":"Turaga K, Ahuja N, Alexander HR Jr,  The Chicago Consensus Guidelines for peritoneal surface malignancies: introduction. Cancer 2020;126:2510\u20132512."},{"key":"B3","series-title":"Eur J Surg Oncol","first-page":"36","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura S","year":"2021","unstructured":"Kusamura S, Kepenekian V, Villeneuve L,  Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47:36\u201359."},{"key":"B11","article-title":"NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Peritoneal","author":"Ettinger DS","unstructured":"Ettinger DS, Wood DE, Stevenson J,  NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Peritoneal. Version 1.2023. Accessed May 1, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B12","series-title":"Cancer","first-page":"2547","article-title":"The Chicago Consensus on peritoneal surface malignancies: management of peritoneal mesothelioma","volume":"126","author":"Schuitevoerder D","year":"2020","unstructured":"Schuitevoerder D, Izquierdo FJ, Plana A,  The Chicago Consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. Cancer 2020;126:2547\u20132552."},{"key":"B13","series-title":"Ann Oncol","first-page":"348","article-title":"Malignant peritoneal mesothelioma: a multicenter study on 81 cases","volume":"21","author":"de Pangher Manzini V","year":"2010","unstructured":"de Pangher Manzini V, Recchia L, Cafferata M,  Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010;21:348\u2013353."},{"key":"B14","series-title":"Tumori","first-page":"269","article-title":"Clinical presentation of peritoneal mesothelioma","volume":"89","author":"Acherman YI","year":"2003","unstructured":"Acherman YI, Welch LS, Bromley CM,  Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269\u2013273."},{"key":"B15","series-title":"J Thorac Oncol","first-page":"608","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter JL","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F,  The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol 2022;17:608\u2013622."},{"key":"B16","series-title":"Arch Pathol Lab Med","first-page":"89","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain AN","year":"2018","unstructured":"Husain AN, Colby TV, Ord\u00f3\u00f1ez NG,  Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018;142:89\u2013108."},{"key":"B17","series-title":"J Gastrointest Oncol","first-page":"915","article-title":"Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review","volume":"8","author":"Garc\u00eda-Fadrique A","year":"2017","unstructured":"Garc\u00eda-Fadrique A, Mehta A, Mohamed F,  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol 2017;8:915\u2013924."},{"key":"B18","series-title":"J Clin Pathol","first-page":"847","article-title":"Challenges and controversies in the diagnosis of mesothelioma: part 1. cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers","volume":"66","author":"Henderson DW","year":"2013","unstructured":"Henderson DW, Reid G, Kao SC,  Challenges and controversies in the diagnosis of mesothelioma: part 1. cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 2013;66:847\u2013853."},{"key":"B19","series-title":"The MD Anderson Surgical Oncology Handbook","first-page":"281","article-title":"Peritoneal malignancies","author":"Grotz","year":"2019","unstructured":"Grotz, Keith F. Fournier, Mann GN. Peritoneal malignancies. In: Feig BW, Ching CD, eds. The MD Anderson Surgical Oncology Handbook, 6th ed. Wolters Kluwer; 2019:281\u2013303."},{"key":"B20","series-title":"Ann Surg Oncol","first-page":"667","article-title":"Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry","volume":"25","author":"Votanopoulos KI","year":"2018","unstructured":"Votanopoulos KI, Sugarbaker PH, Deraco M,  Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol 2018;25:667\u2013673."},{"key":"B21","series-title":"Eur J Surg Oncol","first-page":"1047","article-title":"Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","volume":"36","author":"Baratti D","year":"2010","unstructured":"Baratti D, Vaira M, Kusamura S,  Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur J Surg Oncol 2010;36:1047\u20131053."},{"key":"B22","series-title":"Eur J Surg Oncol","first-page":"948","article-title":"Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma","volume":"32","author":"Yan TD","year":"2006","unstructured":"Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948\u2013953."},{"key":"B23","series-title":"J Exp Clin Cancer Res","first-page":"49","article-title":"Current methodologies for clinical assessment of patients with peritoneal carcinomatosis","volume":"15","author":"Jacquet P","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49\u201358."},{"key":"B24","series-title":"Cancer Treat Res","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet P","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u2013374."},{"key":"B25","series-title":"Br J Radiol","first-page":"20190163","article-title":"Accuracy of radiologic-laparoscopic peritoneal carcinomatosis categorization in the prediction of surgical outcome","volume":"92","author":"Ahmed SA","year":"2019","unstructured":"Ahmed SA, Abou-Taleb H, Ali N,  Accuracy of radiologic-laparoscopic peritoneal carcinomatosis categorization in the prediction of surgical outcome. Br J Radiol 2019;92:20190163."},{"key":"B26","series-title":"J Surg Oncol","first-page":"565","article-title":"Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study","volume":"102","author":"Esquivel J","year":"2010","unstructured":"Esquivel J, Chua TC, Stojadinovic A,  Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol 2010;102:565\u2013570."},{"key":"B27","series-title":"Ann Surg Oncol","first-page":"1708","article-title":"Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures","volume":"22","author":"Low RN","year":"2015","unstructured":"Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 2015;22:1708\u20131715."},{"key":"B28","series-title":"Br J Surg","first-page":"1244","article-title":"Evaluation of the peritoneal carcinomatosis index with CT and MRI","volume":"104","author":"Dohan A","year":"2017","unstructured":"Dohan A, Hoeffel C, Soyer P,  Evaluation of the peritoneal carcinomatosis index with CT and MRI. Br J Surg 2017;104:1244\u20131249."},{"key":"B29","series-title":"Ann Surg Oncol","first-page":"555","article-title":"A novel nomogram for peritoneal mesothelioma predicts survival","volume":"20","author":"Schaub NP","year":"2013","unstructured":"Schaub NP, Alimchandani M, Quezado M,  A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol 2013;20:555\u2013561."},{"key":"B30","series-title":"Sci Rep","first-page":"13257","article-title":"Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study","volume":"10","author":"Salo SAS","year":"2020","unstructured":"Salo SAS, Lantto E, Robinson E,  Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study. Sci Rep 2020;10:13257."},{"key":"B31","series-title":"Cancer","first-page":"839","article-title":"Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy","volume":"103","author":"Yan TD","year":"2005","unstructured":"Yan TD, Haveric N, Carmignani CP,  Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103:839\u2013849."},{"key":"B32","series-title":"Int Semin Surg Oncol","first-page":"3","article-title":"Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer","volume":"2","author":"Harmon RL","year":"2005","unstructured":"Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:3."},{"key":"B33","series-title":"Br J Radiol","first-page":"20170361","article-title":"Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre","volume":"90","author":"Chandramohan A","year":"2017","unstructured":"Chandramohan A, Thrower A, Shah N,  Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. Br J Radiol 2017;90:20170361."},{"key":"B34","series-title":"Cancer","first-page":"1855","article-title":"A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database","volume":"117","author":"Yan TD","year":"2011","unstructured":"Yan TD, Deraco M, Elias D,  A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011;117:1855\u20131863."},{"key":"B35","series-title":"In Vivo","first-page":"187","article-title":"Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma","volume":"23","author":"Laterza B","year":"2009","unstructured":"Laterza B, Kusamura S, Baratti D,  Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009;23:187\u2013190."},{"key":"B36","series-title":"Indian J Surg Oncol","first-page":"230","article-title":"Diagnostic laparoscopy in the pre-operative assessment of patients undergoing cytoreductive surgery and HIPEC for peritoneal surface malignancies","volume":"7","author":"Seshadri RA","year":"2016","unstructured":"Seshadri RA, Hemanth Raj E Diagnostic laparoscopy in the pre-operative assessment of patients undergoing cytoreductive surgery and HIPEC for peritoneal surface malignancies. Indian J Surg Oncol 2016;7:230\u2013235."},{"key":"B37","series-title":"Ann Surg Oncol","first-page":"1686","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm JH","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA,  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686\u20131693."},{"key":"B38","series-title":"Eur J Surg Oncol","first-page":"2292","article-title":"Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS) Society recommendations - part I: preoperative and intraoperative management","volume":"46","author":"H\u00fcbner M","year":"2020","unstructured":"H\u00fcbner M, Kusamura S, Villeneuve L,  Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS) Society recommendations - part I: preoperative and intraoperative management. Eur J Surg Oncol 2020;46:2292\u20132310."},{"key":"B39","series-title":"Ann Surg Oncol","first-page":"1416","article-title":"Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study","volume":"19","author":"Baratti D","year":"2012","unstructured":"Baratti D, Kusamura S, Cabras AD,  Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol 2012;19:1416\u20131424."},{"key":"B40","series-title":"Ann Surg","first-page":"29","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker PH","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29\u201342."},{"key":"B41","series-title":"Ann Surg Oncol","first-page":"768","article-title":"Is routine omentectomy a necessary component of cytoreductive surgery and HIPEC?","volume":"30","author":"Khan S","year":"2023","unstructured":"Khan S, Doan NH, Hosseini M,  Is routine omentectomy a necessary component of cytoreductive surgery and HIPEC? Ann Surg Oncol 2023;30:768\u2013773."},{"key":"B42","series-title":"Ann Surg Oncol","first-page":"45","article-title":"Lymph node metastases in diffuse malignant peritoneal mesothelioma","volume":"17","author":"Baratti D","year":"2010","unstructured":"Baratti D, Kusamura S, Cabras AD,  Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010;17:45\u201353."},{"key":"B43","series-title":"Surg Oncol Clin N Am","first-page":"689","article-title":"Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents","volume":"12","author":"Sticca RP","year":"2003","unstructured":"Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003;12:689\u2013701."},{"key":"B44","series-title":"Cancer Res","first-page":"1252","article-title":"A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity","volume":"52","author":"Los G","year":"1992","unstructured":"Los G, Smals OA, van Vugt MJ,  A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992;52:1252\u20131258."},{"key":"B45","series-title":"Am Surg","first-page":"348","article-title":"Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma","volume":"80","author":"Shetty SJ","year":"2014","unstructured":"Shetty SJ, Bathla L, Govindarajan V,  Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg 2014;80:348\u2013352."},{"key":"B46","series-title":"Int J Hyperthermia","first-page":"565","article-title":"Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence","volume":"30","author":"Vaira M","year":"2014","unstructured":"Vaira M, Robella M, Mellano A,  Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int J Hyperthermia 2014;30:565\u2013569."},{"key":"B47","series-title":"Ann Surg Oncol","first-page":"1680","article-title":"Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome","volume":"22","author":"Ihemelandu C","year":"2015","unstructured":"Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol 2015;22:1680\u20131685."},{"key":"B48","series-title":"Cancer","first-page":"1144","article-title":"Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique","volume":"106","author":"Kusamura S","year":"2006","unstructured":"Kusamura S, Younan R, Baratti D,  Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006;106:1144\u20131153."},{"key":"B49","series-title":"Ann Surg Oncol","first-page":"2550","article-title":"Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity","volume":"14","author":"Kusamura S","year":"2007","unstructured":"Kusamura S, Baratti D, Younan R,  Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol 2007;14:2550\u20132558."},{"key":"B50","series-title":"Eur J Surg Oncol","first-page":"2311","article-title":"Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS) Society recommendations - part II: postoperative management and special considerations","volume":"46","author":"H\u00fcbner M","year":"2020","unstructured":"H\u00fcbner M, Kusamura S, Villeneuve L,  Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS) Society recommendations - part II: postoperative management and special considerations. Eur J Surg Oncol 2020;46:2311\u20132323."},{"key":"B51","series-title":"Int J Surg Case Rep","first-page":"108359","article-title":"Response to nivolumab followed by complete cytoreductive surgery with HIPEC resulted in long-term survival in a patient with sarcomatoid-predominant biphasic peritoneal mesothelioma. A case report","volume":"107","author":"Sugarbaker PH","year":"2023","unstructured":"Sugarbaker PH. Response to nivolumab followed by complete cytoreductive surgery with HIPEC resulted in long-term survival in a patient with sarcomatoid-predominant biphasic peritoneal mesothelioma. A case report. Int J Surg Case Rep 2023;107:108359."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/9\/article-p981.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/9\/article-p981.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/9\/article-p981.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T19:35:46Z","timestamp":1694028946000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/9\/article-p981.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":51,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7055","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}